Kyntra Bio (KYNB) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of a loss of $3.66. This compares to a loss of $1.61 per share a year ago.
KYNB's reported revenue has swung erratically, from $46.3M in 2024Q3 to roughly $1.8M in 2026Q3, making a durable growth trajectory difficult to establish, while operating income remained deeply negative at -$12.9M in the latest quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | $0.04+101.1% vs -$3.55 | $2M+1.9% vs $2M |
Q3 2026 Aug 13, 2026 | $2.96+193.1% vs -$3.18 | $2M-171.8% vs $2M |
Q2 2026 May 11, 2026 | -$3.74-11.3% vs -$3.36 | $4M+137.9% vs $2M |
Q2 2026 Mar 16, 2026 | -$3.51+9.8% vs -$3.89 | $1M-22.2% vs $2M |
Kyntra Bio (KYNB) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of a loss of $3.66. This compares to a loss of $1.61 per share a year ago.
Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise Decision to discontinue development of FG-3246 and FG-3180 following insufficient efficacy at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer (mCRPC), resulting in a reduction of over $20 million in operating expenses in 2027 and 2028 Cash, cash equivalents, investments, and accounts receivable of $44.1 million as of September 30, 2026, with a cash runway now into 2028 Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company's recent developments. “Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio.

SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Kyntra Bio Inc (NASDAQ: KYNB - Get Free Report) has earned an average rating of "Hold" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts
Benchmark KYNB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Kyntra Bio, Inc. (KYNB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.04 | $8.26M | 0.24 | -78.26% | 657.67% | 4099.49% | — | |
| $0.40 | $107.41M | -2.49 | 47.46% | -22.6% | -169.15% | — | |
| $60.36 | $5.01B | -47.55 | 114.51% | -9.17% | — | — | |
| $16.70 | $1.64B | -3.25 | 20.13% | -71.78% | — | — | |
| $121.86 | $26.41B | -44.02 | 66.73% | -39.85% | -82.75% | — | |
| $42.99 | $6.06B | -8.41 | -45.65% | -160.64% | -172.62% | — |
Kyntra Bio, Inc. (KYNB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Kyntra Bio, Inc. (KYNB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 6, 2026·SEC
Oct 1, 2026·SEC
Aug 31, 2026·SEC
Get notified when KYNB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kyntra Bio, Inc. (KYNB) stock FAQ — growth, dividends, profitability & financials explained
Kyntra Bio, Inc. (KYNB) reported $5.3M in revenue over the trailing twelve months. Revenue was $6.4M in fiscal year 2025. That is 90% less than the $65.9M of fiscal year 2012.
Kyntra Bio, Inc. (KYNB) grew revenue by 104.5% over the trailing twelve months, compared with the twelve months before.
Yes. Kyntra Bio, Inc. (KYNB) earned $34.9M in net income over the trailing twelve months (a 657.7% net margin).
Kyntra Bio, Inc. (KYNB) had a return on equity (ROE) of 4099.5% in fiscal year 2025. That is well above the market's typical 10-15%.
Kyntra Bio, Inc. (KYNB) had negative free cash flow of $48.5M over the trailing twelve months.